Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research CouncilVIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral DrugsLexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (“NRC”). Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)Lexaria Bioscience Corp. (CSE;LXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology “did not negate the known efficacy of those compounds.” Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral DrugsDehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic (“PK”) animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine. Lexaria’s DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 VirusLexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3. |